CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Inveresk Research Group, Inc. for approximately $1.5 billion, a transaction completed in October 2004, structured as cash and stock. The deal was a Merger.
Inveresk Research Group, Inc. operates in Discovery and Safety Assessment (DSA), is based in United Kingdom (Edinburgh, Scotland). Inveresk Research Group was a NASDAQ-listed (IRGI) global contract research organization providing preclinical and clinical drug development services. The combination created a broader early-stage CRO spanning research models through clinical-stage development.
Charles River announced that it has completed its merger with Inveresk Research Group, Inc. The transaction was approved by shareholders of each company at special meetings held today.
Folded into Charles River's drug development / safety assessment operations
Advisory firms were not disclosed for this transaction.